Labcorp has begun rolling out a new blood test that aims to predict the risk of a pregnant person developing preeclampsia, ...
According to AltruBio, the new lead prospect has shown improved potency in down-regulating chronic pathogenic T cells in ...
Johnson & Johnson MedTech’s Biosense Webster division presented new clinical data backing up its pulsed field ablation ...
AstraZeneca’s growing presence in China will play a key role in the Big Pharma’s cell therapy strategy, CEO Pascal Soriot ...
Lilly established itself as a player in the nascent radiopharma space by acquiring Point Biopharma for $1.4 billion late last ...
Exscientia is initiating “efficiency measures” to save cash, which will include a workforce reduction of around a quarter of ...
Larimar Therapeutics’ Friedreich’s ataxia program is free at last, with the FDA fully lifting a clinical hold that had ...
The Catalogue of Somatic Mutations in Cancer, or COSMIC, has launched its 100th version, parent institution Wellcome Sanger ...
It’s not a double album release, but it’s a close runner-up: the pivotal SWIFT-1 and SWIFT-2 trials have shown that GSK's ...
The so-called “Clinical Trial in a Dish” can purportedly save drug companies up to $1 billion and more than six years of development time.
Biometrics contract research organization Phastar is integrating technology from Beaconcure, a trial data analytics software provider, into clients’ trial operations, according to a May 20 release.
Endeavor BioMedicines has linked its Hedgehog inhibitor to improved lung function in a phase 2a idiopathic pulmonary fibrosis ...